4084-27-9
基本信息
3-脱氧-D-葡糖醛酮
3-DEOXYGLUCOSONE
3-DEOXYGLUCOSONE
d-3-deoxyglucosone
3-Deoxy-D-glucosone
2-Keto-3-deoxyglucose
3-Deoxy-D-glucosone ,95%
2-Keto-3-Deoxyglucose-13C
3-Deoxy-D-erythro-hexulose
3-deoxy-d-erythro-hexosulos
3-Deoxy-D-erythro-hexosulose
物理化学性质
| 熔点 | 73-75°C |
| 沸点 | 208.81°C (rough estimate) |
| 密度 | 1.2132 (rough estimate) |
| RTECS号 | MQ3390000 |
| 折射率 | 1.4230 (estimate) |
| 储存条件 | Hygroscopic, -20°C Freezer, Under Inert Atmosphere |
| 溶解度 | 可溶于甲醇（轻微）、水（轻微、超声处理） |
| 酸度系数(pKa) | 13.17±0.20(Predicted) |
| 形态 | 固体 |
| 颜色 | 黄色 |
| 水溶解性 | Soluble in water, methanol or hot ethanol. |
| 稳定性 | 吸湿性 |
| InChI | 1S/C6H10O5/c7-2-5-3(8)1-4(9)6(10)11-5/h3,5-8,10H,1-2H2/t3-,5+,6?/m0/s1 |
| InChIKey | UHPMJDGOAZMIID-OPAZFOKUSA-N |
| SMILES | OC[C@H]1OC(O)C(=O)C[C@@H]1O |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H315-H319-H335 |
| 防范说明 | P260-P271-P280 |
| 危险品标志 | Xi |
| 安全说明 | 24/25 |
| WGK Germany | 3 |
| 海关编码 | 29329990 |
| 存储类别 | 11 - Combustible Solids |
3-脱氧葡萄糖醛酮价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-N7426 | 3-脱氧葡萄糖醛酮 3-Deoxyglucosone | 4084-27-9 | 1 mg | 1520元 |
| 2026/09/15 | HY-N7426 | 3-脱氧葡萄糖醛酮 3-Deoxyglucosone | 4084-27-9 | 5 mg | 3800元 |
常见问题列表
3-Deoxyglucosone (80 ng/ml-1000 ng/ml; 1 hour) markedly increases GLP-1 secretion by 1.23-folds in 300 ng/ml or 1000 ng/ml 3DG-treated group. But at alower concentration (80 ng/ml) has no effects.3-Deoxyglucosone (300 ng/ml; 1 hour) dramatically increases intracellular Ca 2+ levels by Fluo-3/AM determination (2.5 μM for 30 mins). But 3DG does not affect intracellular cAMP levels in a cAMP Elisa assay.3-Deoxyglucosone (300 ng/ml; 1 hour) significantly increases the protein expression levels of TAS1R2, TAS1R3, and TRPM5 under both glucose-free and highconditions.
Western Blot Analysis
| Cell Line: | STC-1 cells |
| Concentration: | 300 ng/ml |
| Incubation Time: | 1 hour |
| Result: | Upregulated TAS1R2, TAS1R3, and TRPM5 expression. |
3-Deoxyglucosone (intragastric administration; 20 mg/kg; single dose) impairs glucose tolerance with increased AUC, but the plasma glucagon levels are not significantly different. It developes impaired glucose regulation (IGR) with obviously pancreatic islet cell dysfunction in kunming mice and SD-rats.3-deoxyglucosone (gastric gavage; 5-50 mg/kg; once daily; 2 weeks) is significantly increased in the upper small intestine (1.4-fold), lower small intestine (1.4-fold), ileum (1.4-fold) and colon (two fold) compared with the basal levels in the corresponding control group. In addition, the protein expressions of TAS1R2, TAS1R3 and TRPM5 in both duodenum and colon are significantly decreased.
| Animal Model: | SD rats |
| Dosage: | 5, 20 and 50 mg/kg |
| Administration: | oral administration; once daily; 2 weeks |
| Result: | Was capable of accumulating in intestinal tissue and thereby decreased secretion of GLP-1 and insulin. |